Revenue, R&D and Biotech’s Future

Special purpose acquisition companies (SPACs) nearly went the way of the dinosaur after the 2007–2008 financial crisis. However, COVID-19 has seemingly brought them back to life as pandemic-driven market volatility continues to disrupt and complicate the traditional path to an IPO.

IPOs can be a thrilling milestone, but transforming into a public entity is not an easy undertaking. A successful IPO requires significant focus, as well as time and resource investment, before stakeholders get to ring the bell. Biotech companies should consider the following steps—and answer the corresponding questions—ahead of IPO consideration.

Nothing returns to normal without life sciences. Tasked with charting a sustainable road to recovery for both the industry and the global economy at large, life sciences CFOs feel confident about the pivots they made in crisis and are optimistic for growth in 2021.